Supplementary Table 2. Baseline characteristics for participants with IV thrombolysis and without reperfusion treatment, before and after propensity score matching.

	Unmatched				Matched			
	No reperfusion treatment (n=2766)	IV Thrombolysis (n=955)	P-value	SMD	No reperfusion treatment (n=824)	IV Thrombolysis (n=824)	P-value	SMD
Cohort			<0.001	0.988			0.446	0.177
Austria	357 (13%)	100 (11%)			117 (14%)	100 (12%)		
Germany (1)	123 (5%)	43 (5%)			49 (9%)	41 (8%)		
Italy	388 (14%)	11 (1%)			13 (2%)	11 (1%)		
Portugal	50 (2%)	101 (11%)			50 (6%)	74 (9%)		
Spain	259 (9%)	236 (25%)			150 (18%)	185(23%)		
Switzerland (1)	1061 (38%)	139 (15%)			161 (20%)	139 (17%)		
Switzerland (2)	528 (19%)	325 (34%)			279 (34%)	272 (33%)		
Age	74 (63-82)	73 (62-81)	0.01*	0.089	73 (61-82)	73 (62-80)	0.42	0.014
Sex (Male)	1563(57%)	563 (59%)	0.20	0.050	471(57%)	488 (59%)	0.40	0.042
NIHSS at admission								
0-3	1541(56%)	116 (12%)	Ref.	Ref.	120 (15%)	112 (13%)	Ref-	Ref-
4-10	826 (30%)	414 (43%)	<0.001	0.283	412 (50%)	392 (48%)	0.32	0.049
≥11	410 (1516%)	429 (45%)	<0.001	0.696	292 (35%)	320 (39%)	0.15	0.070
Stroke etiology								
Large-artery atherosclerosis	473 (17%)	215(23%)	<0.001	0.136	176 (21%)	188 (23%)	0.47	0.013
Small-vessel occlusion	751 (27%)	102 (11%)	<0.001	0.430	98 (12%)	95 (12%)	0.82	0.035
Cardioembolic	778 (28%)	331 (35%)	<0.001	0.141	308 (37%)	280 (34%)	0.15	0.011
Stroke location								
MCA territory	1760 (63%)	729 (76%)	<0.001	0.280	600 (73%)	612 (74%)	0.50	0.033
Cortical involvement	1358 (49%)	564 (59%)	<0.001	0.201	500 (61%)	489 (59%)	0.58	0.027
ASM treatment after ASS	100 (4%)	69 (7%)	<0.001	0.160	57 (7%)	55 (7%)	0.84	0.010

NIHSS = National Institutes of Health Stroke Scale; MCA = middle cerebral artery; ASM = anti-seizure medication; ASS= acute symptomatic seizures; SMD = standardized mean difference; * p-value is for Wilcoxon rank-sum test